Integrin antagonists
US5981546A · kind A · utility
19Cited by
4References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 18, 1997 |
| Grant date | Nov 9, 1999 |
| Priority date | — |
| Expiry date | Aug 18, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.